DNA Ploidy Status and Prognosis in Colorectal Cancer: A Meta-Analysis of Published Data

DNA Ploidy Status and Prognosis in Colorectal Cancer: A Meta-Analysis of Published Data

PURPOSE: METHODS: RESULTS:A total of 5,478 patients with colorectal cancer were represented in 32 studies (Group 1), we estimated a reduction in the five-year overall mortality from 43.2 percent for aneuploid tumors to 29.2 percent for diploid tumors (combined relative risk = 1.44; 95 percent confid...

Full description

Saved in:
Bibliographic Details
Published in:Diseases of the colon & rectum Vol. 50; no. 11; pp. 1800 - 1810
Main Authors: Araujo, Sergio E. A, Bernardo, Wanderley M, Habr-Gama, Angelita, Kiss, Desiderio R, Cecconello, Ivan
Format: Journal Article
Language:English
Published: Secaucus, NJ The ASCRS 01-11-2007
Springer
Lippincott Williams & Wilkins Ovid Technologies
Subjects:
Aneuploidy
Biological and medical sciences
Chromosome aberrations
Colorectal cancer
Colorectal Neoplasms - genetics
Colorectal Neoplasms - mortality
DNA, Neoplasm - genetics
Gastroenterology. Liver. Pancreas. Abdomen
Humans
Medical genetics
Medical sciences
Prognosis
Publication Bias
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Survival Analysis
Tumors
Chromosomal aberration
Ploidy
Rectal disease
Prognosis
Colorectal cancer
Aneuploidy
Malignant tumor
Colorectal neoplasms
Colonic neoplasms
Rectal neoplasms
Meta-analysis
Colonic disease
DNA
Ploidies
Rectum
Digestive diseases
Intestinal disease
Colon
Cancer
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:PURPOSE: METHODS: RESULTS:A total of 5,478 patients with colorectal cancer were represented in 32 studies (Group 1), we estimated a reduction in the five-year overall mortality from 43.2 percent for aneuploid tumors to 29.2 percent for diploid tumors (combined relative risk = 1.44; 95 percent confidence interval = 1.34-1.55; P < 0.001). In addition, 357 patients with Stage II colon cancer (Group 2) extracted from three studies had an absolute reduction of 14.3 percent in five-year overall mortality favoring diploid tumors (combined relative risk = 1.93; 95 percent confidence interval = 1.29-2.89; P = 0.001). Lastly, of 14 studies in which follow-up losses were declared (Group 3), 2,221 patients were represented and a 15.7 percent mortality reduction was measured favoring patients with diploid tumors (combined relative risk = 1.44; 95 percent confidence interval = 1.3-1.61; P < 0.001). CONCLUSIONS:
Bibliography:ObjectType-Article-2
SourceType-Scholarly Journals-1
ObjectType-Feature-1
ObjectType-Review-3
content type line 23
ISSN:0012-3706
1530-0358
DOI:10.1007/s10350-007-9013-6